Chronic kidney disease stage 5 as the prognostic complement of International Staging System for multiple myeloma. - Wikidata - wikimedia - TriplyDB

Chronic kidney disease stage 5 as the prognostic complement of International Staging System for multiple myeloma.

Chronic kidney disease stage 5 as the prognostic complement of International Staging System for multiple myeloma.

http://www.wikidata.org/entity/Q33397490

about

Renal Function and All-Cause Mortality Risk Among Cancer Patients Cancer and the kidney: dangereoux liasons or price paid for the progress in medicine?Pre-existing diabetes mellitus in patients with multiple myeloma.

P2860

Q36993190-334A3844-8466-472F-ACC6-8767064D8BB9 Q42371674-34C977C4-749B-4BE3-B053-56D3FDCD763C Q48651168-10CE9DE2-F141-4A5F-8F80-7367F80F98BE

P2860

Chronic kidney disease stage 5 as the prognostic complement of International Staging System for multiple myeloma.

http://www.wikidata.org/entity/Q33397490

description

2011 nî lūn-bûn

@nan

2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Chronic kidney disease stage 5 ...... g System for multiple myeloma.

@ast

Chronic kidney disease stage 5 ...... g System for multiple myeloma.

@en

type

label

Chronic kidney disease stage 5 ...... g System for multiple myeloma.

@ast

Chronic kidney disease stage 5 ...... g System for multiple myeloma.

@en

prefLabel

Chronic kidney disease stage 5 ...... g System for multiple myeloma.

@ast

Chronic kidney disease stage 5 ...... g System for multiple myeloma.

@en

P1433

Q33397490-B1D18E04-FBD8-405F-9C7C-248C597FA6C9

P1476

Q33397490-96833BEB-E25F-4F1D-AABF-733AF154EB4A

P2093

Q33397490-120466A1-457A-406F-8533-F128D095ABEF

Q33397490-1822C614-AC6D-4A2C-A213-F31219B9C105

Q33397490-18BC006E-76D8-48C2-97EE-6E2D370DDBC4

Q33397490-4FB91638-E026-4DE3-98BF-7DF609DB3D16

Q33397490-89A47309-8545-445A-BA1B-C8538099F96B

Q33397490-90C84FE2-F0FC-4B67-AFFB-75B5CFE816E3

Q33397490-B7FEC32A-0EAE-471E-803F-89BF0952783A

Q33397490-C6F043C9-94ED-4A50-9DCE-79AA1AEBCA01

Q33397490-DB49B5AF-8F68-477E-B84D-A2B277E66A47

Q33397490-F0D921E2-01DB-4A0D-A259-A5E94F5EB08E

P2860

Q33397490-15D0DF4D-1FBC-4176-8E01-3AD204577F59

Q33397490-1CDAEC3B-A93B-4901-9D81-7F63B901E6D0

Q33397490-1D95139B-A9E0-46FD-B2D2-635B56CF46C5

Q33397490-28CC0195-F313-4155-AEFD-17DFB61105A1

Q33397490-36621EF7-C608-4B4C-9392-2D6F1020584D

Q33397490-501B9C0C-7D85-4CCF-A165-58BEA59E7846

Q33397490-525B90C4-6F0C-4BB9-B959-B428B6C88BA7

Q33397490-5333FAC3-831D-4C71-A87B-8215CA7FBB16

Q33397490-58156EBB-F5AE-43EE-91BA-6AEDA97C83E7

Q33397490-62E35DC4-DF6C-4C13-A0B6-3E67AF897F89

P304

Q33397490-231365CB-2356-4A59-B758-36A4E5977B02

P31

Q33397490-AA45CDFB-D698-4DC6-8FA7-28E90225CA31

P356

Q33397490-330D6083-2BFD-44BE-94C0-0502AAF87EAE

P433

Q33397490-37A3B3EA-8755-4651-B4FD-ECE4B624C9EB

P478

Q33397490-6F67A1D4-237A-4719-8FD9-8E6A40F4CEAD

P577

Q33397490-1B595185-D3C3-41E5-9F5D-E4CBD30D83F1

P698

Q33397490-7E6D5C36-B4DA-414E-BF6F-8FC28A2A3169

P356

J.1600-0609.2011.01717.X

P1433

European Journal of Haematology

P1476

Chronic kidney disease stage 5 ...... g System for multiple myeloma.

@en

P2093

Cheng-Hwai Tzeng

http://www.w3.org/2001/XMLSchema#string

Ching-Fen Yang

http://www.w3.org/2001/XMLSchema#string

Chun-Yu Liu

http://www.w3.org/2001/XMLSchema#string

Jin-Hwang Liu

http://www.w3.org/2001/XMLSchema#string

Jyh-Pyng Gau

http://www.w3.org/2001/XMLSchema#string

Liang-Tsai Hsiao

http://www.w3.org/2001/XMLSchema#string

Po-Min Chen

http://www.w3.org/2001/XMLSchema#string

Sheng-Hsiang Yang

http://www.w3.org/2001/XMLSchema#string

Tzeon-Jye Chiou

http://www.w3.org/2001/XMLSchema#string

Ying-Chung Hong

http://www.w3.org/2001/XMLSchema#string

P2860

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.

International staging system for multiple myeloma.

Review of 1027 patients with newly diagnosed multiple myeloma.

Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration.

Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis.

Comparison of serum beta 2-microglobulin and 24 hour urinary creatinine clearance as a prognostic factor in multiple myeloma.

Kidney disease associated with plasma cell dyscrasias

Epidemiology, impact and preventive care of chronic kidney disease in Taiwan.

Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.

P304

159-166

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1600-0609.2011.01717.X

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

88

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21973045

http://www.w3.org/2001/XMLSchema#string